Factors determining anti-poliovirus type 3 antibodies among orally immunised Indian infants
Factors determining anti-poliovirus type 3 antibodies among orally immunised Indian infants
复制标题
DOI：
10.1016/j.vaccine.2016.08.032
复制
发表时间：
2016-09-22
期刊：
影响因子：
5.5
通讯作者：
Kang, Gagandeep
中科院分区：
文献类型：
--
作者：
Kaliappan, Saravanakumar Puthupalayam;Venugopal, Srinivasan;Kang, Gagandeep
背景：在三种脊髓灰质炎病毒血清型中，接种三价口服脊髓灰质炎疫苗（tOPV）后应答最低的是血清3型。虽然在常规免疫接种和补充免疫活动的改善大大提高了疫苗的覆盖率，有有限的数据抗体流行率在印度infants.Methods：5-11个月的儿童没有收到灭活脊髓灰质炎疫苗的历史进行了筛选血清抗体脊髓灰质炎病毒血清型3（PV 3）的微量中和试验根据修改后的世界卫生组织（WHO）的协议。收集了有限的人口统计学信息，以评估缺乏保护性抗体的风险因素。结果：在平均年龄为8.3（标准差[SD]-1.8）个月时筛查的8454名儿童中，88.1%（95%可信区间（CI）：87.4-88.8）有PV 3保护性抗体。接受的tOPV剂量数是血清阳性率的主要决定因素;最大似然估计值得出每剂tOPV的血清阳性率增加37.7%（95% CI：36.2-38.3）。在多变量logistic回归分析中，年龄增加、男性和城市居住也与血清阳性独立相关（比值比（OR）; 1.17（95% CI：1.12-1.23）每个月龄，1.27（1.11-1.46）和1.24（1.05-1.45））。结论：PV 3抗体阳性率与年龄、性别、居住地及tOPV接种次数有关。只要口服疫苗用于消灭小儿麻痹症，就必须确保高覆盖率和监测反应情况。(C)2016作者爱思唯尔有限公司出版
Background: Among the three poliovirus serotypes, the lowest responses after vaccination with trivalent oral polio vaccine (tOPV) are to serotype 3. Although improvements in routine immunisation and supplementary immunisation activities have greatly increased vaccine coverage, there are limited data on antibody prevalence in Indian infants.Methods: Children aged 5-11 months with a history of not having received inactivated polio vaccine were screened for serum antibodies to poliovirus serotype 3 (PV3) by a micro-neutralisation assay according to a modified World Health Organization (WHO) protocol. Limited demographic information was collected to assess risk-factors for a lack of protective antibodies. Student's t-test, logistic regression and multilevel logistic regression (MLR) model were used to estimate model parameters.Results: Of 8454 children screened at a mean age of 8.3 (standard deviation [SD]-1.8) months, 88.1% (95% confidence interval (Cl): 87.4-88.8) had protective antibodies to PV3. The number of tOPV doses received was the main determinant of seroprevalence; the maximum likelihood estimate yields a 37.7% (95% CI: 36.2-38.3) increase in seroprevalence per dose of tOPV. In multivariable logistic regression analysis increasing age, male sex, and urban residence were also independently associated with seropositivity (Odds Ratios (OR); 1.17 (95% CI: 1.12-1.23) per month of age, 1.27 (1.11-1.46) and 1.24 (1.05-1.45) respectively).Conclusion: Seroprevalence of antibodies to PV3 is associated with age, gender and place of residence, in addition to the number of tOPV doses received. Ensuring high coverage and monitoring of response are essential as long as oral vaccines are used in polio eradication. (C) 2016 The Authors. Published by Elsevier Ltd.